Quick Answer
Aptose Biosciences Inc. reported Stockholders Equity of -$27.17 million for the year ending 2025.
- Aptose Biosciences Inc. showed a decrease of -498.0% in Stockholders Equity from 2024 to 2025.
- This data is from Aptose Biosciences Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $14.47 million | Q2 2018: $16.89 million | Q3 2018: $13.93 million | Q1 2019: $15.42 million | Q2 2019: $33.76 million | Q3 2019: $27.43 million | Q1 2020: $87.24 million | Q2 2020: $79.22 million | Q3 2020: $129.16 million | Q1 2021: $109.41 million | Q2 2021: $98.19 million | Q3 2021: $88.68 million | Q1 2022: $65.28 million | Q2 2022: $55.49 million | Q3 2022: $46.81 million | Q1 2023: $25.99 million | Q2 2023: $13.79 million | Q3 2023: $7.78 million | Q1 2024: $137.0 thousand | Q2 2024: -$2.18 million | Q3 2024: -$9.13 million | Q1 2025: -$7.39 million | Q2 2025: -$14.37 million | Q3 2025: -$19.45 million.
- Over the full 10 years of available data (2016 to 2025), Aptose Biosciences Inc.'s Stockholders Equity has declined by 470.7%.
- Historical annual values: Fiscal year 2025: -$27.17 million | Fiscal year 2024: -$4.54 million | Fiscal year 2023: -$2.90 million | Fiscal year 2022: $37.74 million | Fiscal year 2021: $74.24 million | Fiscal year 2020: $118.92 million | Fiscal year 2019: $93.93 million | Fiscal year 2018: $14.08 million | Fiscal year 2017: $10.20 million | Fiscal year 2016: $7.33 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: